AIIMS Delhi to start second dose trial of Bharat Biotech’s Covaxin on 2-6 years old children by next week
As part of its COVID-19 vaccination trials for children, Bharat Biotech is likely to administer the second dose of Covaxin to children aged between 2 and 6 years next week.
Jul 23, 2021, 06:33 AM IST
Bharat Biotech's Covaxin may soon get WHO approval
Bharat Biotech has handed over all the necessary documents related to Covaxin to WHO, after which the vaccine is now expected to get emergency approval.
Jul 13, 2021, 11:10 AM IST
Documents for emergency use listing of Covaxin submitted to WHO, says Bharat Biotech
A WHO pre-qualification, or a EUL, is necessary for a vaccine company to supply vaccines for global facilities such as Covax or international procurement.
Jul 13, 2021, 07:19 AM IST
Bharat Biotech's Covaxin may get Emergency Use List approval soon, here's what WHO said
World Health Organization may take the decision to include Bharat Biotech's COVID-19 vaccine Covaxin to emergency use list (EUL) within four to six weeks chief scientist Soumya Swaminathan said.
Jul 10, 2021, 18:42 PM IST
Bharat Biotech’s Covaxin's phase 3 trial data looks good: WHO Chief Scientist
Dr Soumya Swaminathan said, “We keep a close eye on all vaccines which have received emergency use listing. We continue to seek more data."
Jul 09, 2021, 07:59 AM IST
As Moderna readies to make an entry into India, list of other COVID-19 vaccine options available
Prime Minister Narendra Modi, has hinted that the supply of COVID-19 vaccines is about to increase in the coming days.
Jul 03, 2021, 23:42 PM IST
Covaxin has overall vaccine efficacy of 77.8%, claims Bharat Biotech in results from Phase 3 trials
Covaxin showed 65.2% protection against the Delta variant (B.1.617.2) of COVID-19.
Jul 03, 2021, 06:02 AM IST
Covaxin deal: Bharat Biotech denies allegations of irregularities, says no advance payment received from Brazil
Brazilian federal prosecutors have opened an investigation into the Covaxin deal, citing comparatively high prices, quick talks and pending regulatory approvals as red flags for the contract signed in February.
Jun 30, 2021, 14:09 PM IST
Brazil suspends Bharat Biotech’s Covaxin order over graft allegations
The Bharat Biotech has said that the pricing of COVAXIN has been clearly established between USD 15-20 per dose for supplies to Governments outside India.
Jun 30, 2021, 11:44 AM IST
Bharat Biotech's Covaxin Coronavirus vaccine may soon get WHO recognition
COVID-19 vaccine 'Covaxin' developed in India moves one more step closer to World Health Organization (WHO) approval. The global health body said on Tuesday that rolling data would start in July, following a pre-submission meeting with Bharat Biotech held on June 23.
Jun 30, 2021, 08:22 AM IST
COVID-19: Bharat Biotech submits Covaxin's Phase III trial data to DCGI, say Govt sources
Bharat Biotech's phase III data of its vaccine have been questioned various times.
Jun 22, 2021, 08:45 AM IST
Bharat Biotech-WHO pre-submission meeting for Covaxin EUL on June 23
Bharat Biotech had informed that it had submitted 90 per cent of the documentation needed for WHO`s EUL.
Jun 17, 2021, 11:27 AM IST
Bharat Biotech: Providing Covaxin for ₹150/dose to the govt is not possible in the long run
Covaxin, the Coronavirus vaccine, maker Bharat Biotech on Tuesday said the price of Covaxin supplied to the Indian government at ₹150 per dose is a non-competitive price and is not sustainable in the long run and requires a higher price to offset part of the cost.
Jun 15, 2021, 16:36 PM IST
Rs 150 per dose not sustainable: Bharat Biotech demands higher price for Covaxin from Centre
Bharat Biotech has so far invested over Rs 500 crores at risk from its own resources for product development, clinical trials and setting up of manufacturing facilities for Covaxin.
Jun 15, 2021, 14:38 PM IST
Bharat Biotech gets CISF security cover at its Hyderabad unit
A unit comprising 64 personnel has been sanctioned that will be headed by an Inspector rank officer.
Jun 14, 2021, 20:15 PM IST
FDA rejects emergency use authorisation for Covaxin in a setback for India-made jab
FDA suggests Biologics Licence Application - a "full approval" mechanism by the FDA for drugs and vaccines - route for approval in the United States
Jun 11, 2021, 11:50 AM IST
Covaxin phase 4 trials to be conducted soon, phase 3 data to be out in July: Bharat Biotech
Bharat Biotech is going to conduct a phase 4 trial of its COVID-19 vaccine, Covaxin, in order to check the real-world effectiveness. The company revealed that the results for the phase 3 trial will be published next month.
Jun 10, 2021, 07:36 AM IST
'Not scientifically designed': Bharat Biotech rejects study that claimed Covaxin less effective than Covishield
The Hyderabad-based COVID vaccine manufacturer also said that it will publish the phase 3 trial data in July and after that, it will be applying for the full licensure of COVAXIN.
Jun 09, 2021, 19:16 PM IST
Covaxin maker Bharat Biotech's Hyderabad campus gets CISF security cover
CISF will take over the security of the Bharat Biotech campus in Hyderabad, Telangana. Total 64 CISF personnel, headed by an inspector-level officer, will provide security starting June 14.
Jun 08, 2021, 20:34 PM IST
Bharat Biotech ties up with Ocugen for Covaxin manufacture, sale in Canada
Ocugen Inc. and Bharat Biotech on Thursday (June 3, 2021) announced that they have entered into an amendment to their Co-development, Supply, and Commercialization Agreement to expand Ocugen's exclusive territory to commercialize Covaxin.
Jun 04, 2021, 07:58 AM IST
